Navitoclax (ABT-263) reduced the growth of cancer cell lines with high DKK3 expression (r = −0.338, p = 0.018 [Pearson’s correlation] and 0.023 [Student’s t test]) (Fig. 4D). This evidence concerns the gene DKK3 and cancer.